Clear Search sequence regions


  • ataciguat (1)
  • benzoic acid (1)
  • cinaciguat (1)
  • endothelium (1)
  • forskolin (1)
  • heme (4)
  • heme- receptor (1)
  • hmr 1766 (1)
  • humans (1)
  • methyl (1)
  • mutagenesis (1)
  • nitric oxide (8)
  • pyrazoles (2)
  • pyridines (2)
  • rats (2)
  • receptor (3)
  • sGC (13)
  • sodium (1)
  • vitamin (1)
  • vitamin b 12 (2)
  • Sizes of these terms reflect their relevance to your search.

    Soluble guanylyl cyclase (sGC), a ubiquitously expressed heme-containing receptor for nitric oxide (NO), is a key mediator of NO-dependent processes. In addition to NO, a number of synthetic compounds that target the heme-binding region of sGC and activate it in a NO-independent fashion have been described. We report here that dicyanocobinamide (CN2-Cbi), a naturally occurring intermediate of vitamin B(12) synthesis, acts as a sGC coactivator both in vitro and in intact cells. Heme depletion or heme oxidation does not affect CN2-Cbi-dependent activation. Deletion mutagenesis demonstrates that CN2-Cbi targets a new regulatory site and functions though a novel mechanism of sGC activation. Unlike all known sGC regulators that target the N-terminal regulatory regions, CN2-Cbi directly targets the catalytic domain of sGC, resembling the effect of forskolin on adenylyl cyclases. CN2-Cbi synergistically enhances sGC activation by NO-independent regulators 3-(4-amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine (BAY41-2272), 4-[((4-carboxybutyl){2-[(4-phenethylbenzyl)oxy]phenethyl}amino) methyl [benzoic]-acid (cinaciguat or BAY58-2667), and 5-chloro-2-(5-chloro-thiophene-2-sulfonylamino-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide sodium salt (ataciguat or HMR-1766). BAY41-2272 and CN2-Cbi act reciprocally by decreasing the EC(50) values. CN2-Cbi increases intracellular cGMP levels and displays vasorelaxing activity in phenylephrine-constricted rat aortic rings in an endothelium-independent manner. Both effects are synergistically potentiated by BAY41-2272. These studies uncover a new mode of sGC regulation and provide a new tool for understanding the mechanism of sGC activation and function. CN2-Cbi also offers new possibilities for its therapeutic applications in augmenting the effect of other sGC-targeting drugs.

    Citation

    Iraida Sharina, Michael Sobolevsky, Marie-Francoise Doursout, Dorota Gryko, Emil Martin. Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain. The Journal of pharmacology and experimental therapeutics. 2012 Mar;340(3):723-32

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 22171090

    View Full Text